A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.
Future Oncol
; 12(22): 2589-2602, 2016 Nov.
Article
en En
| MEDLINE
| ID: mdl-27443691
ABSTRACT
To gain consensus on the role of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer, a panel of expert oncologists experienced in treating patients with metastatic breast cancer in Italy participated in a Delphi consensus study. The panel reached a full consensus on the efficacy of bevacizumab plus paclitaxel and the clinical meaningfulness of the progression-free survival benefit compared with paclitaxel alone, despite the lack of an overall survival effect in clinical trials. The participants agreed that real-world data support the effectiveness and well-defined safety profile of the regimen. Views on the use of bevacizumab plus paclitaxel in specific patient populations were not unanimous and clinical judgment remains important. Nevertheless, a high level of agreement was reached.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Bevacizumab
/
Recurrencia Local de Neoplasia
Límite:
Female
/
Humans
País como asunto:
Europa
Idioma:
En
Año:
2016
Tipo del documento:
Article